CardiovascularMAP®
A Multi-Analyte-Profile (MAP) combining analytes most commonly associated with cardiovascular disease. Like all Rules-Based Medicine’s (RBM) MAPs, it is used to identify useful patterns indicative of the effects of either disease or therapeutic intervention. RBM’s MAP approach provides investigators with a reliable platform and quantitative immunoassay data that can help discern biomarker patterns in a cost-effective, efficient process.
Click or mouse over biomarkers for more information. Analytes included in this MAP are subject to change.
Don't See Your Biomarker? Request It »1 This assay did not meet performance specifications in EDTA-Plasma and results should be used for information purposes only.
2 This assay did not meet performance specifications in Serum and results should be used for information purposes only.
Intended for Research Use Only.
| Serum or plasma | Other fluids* |
|---|---|
| 160 µL | 700 µL |
Bibliography
Cancer
2022
Pre- and post-operative psychological interventions to prevent pain and fatigue after breast cancer surgery (PREVENT): Protocol for a randomized controlled trial (2022) Silje Endresen Reme, Alice Munk, Marianne Therese Smogeli Holter, Ragnhild S. Falk, Henrik Børsting Jacobsen Plos One
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis (2022) Claire Harrison Florian H. Heidel, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Amjad Hayat, Francesco Passamonti, Eibhlin Conneally, Thomas Kindler, Bruno Martino,9 Daniel B. Lipka, Tommaso Stefanelli, Pantelia Roussou,Davide Germano,Jacqueline Ewan, and Vincent Ribrag Hemasphere
Back To Top
2021
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy (2021) Choueiri TK, Atkins MB, Rose TL, Alter RS, Yawen J, Niland K, Wang Y, Arbeit R, Parasuraman S, Gan L, McDermott DF Investigational New Drugs
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial (2021) Dowlati A, Jarvey RD, Carvajal RD, Hamid O, Klempner SJ, Wook Kauh JS, Peterson DA, Yu D, CHapman SC, Szpurka AM, Carlsen M, Quinlan T, Wesolowski R Investigational New Drugs
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC (2021) Ross-Macdonald P, Walsh AM, Chasalow SD, Ammar R, Papillon-Cavanagh S, Szabo pm, Choueiri TK, Sznol M, Wind-Rotolo M Journal for Immunotherapy for Cancer
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma (2021) Lee CH, Motzer RJ, Glen H, Michaelson MD, Larkin J, Minoshima Y, Kanekiyo M, Ikezawa H, Sachdev P, Dutcus CE, Funashashi Y, Voss MH British Journal of Cancer
Nonclinical development of SRK-181: An anti-latent TGFb1 monoclonal antibody for the treatment of locally advanced or metastatic solid tumors (2021) Welsh BT, Faucette R, Bilic S, Martin CJ, Schurpf T, Chen D, Nicholls S, Lansita J, Kalra A International Journal of Toxicology
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results (2021) Advani R, Moskowitz AJ, Bartlett NL, Vose J, Ramchandren R, Feldman T, LaCasce AS, Christian B, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF Blood
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab teserine in patients with small cell lung cancer (2021) Calvo E, Spira A, de Miguel M, Kondo S, Gazzah A, Millward M, Prenen H, Rottey S, Warburon L, Alanko T, Cassier PA, Yoh K, Italiano A, Moreno V, Peltola K, Seto T, Toyozawa R, Afar DE, Englert S, Komarnitsky P, Lambert S, Parikh A, Vosganian G, Gao B Cancer Treatment and Research Communities
Biomarker signature in cancer patients with and without venous thromboembolism events: a substudy of CASSINI (2021) Khorana A, Barnard J, Wun T, Vijapurkar U, Damaraju CV, Moore K, Wildgoose P, McCrae K Blood Advances
Combination of atezolizumab and obinutuzumab in patients with relapsed/refractory follicular lymphoma and diffuse large B-cell lymphome: Results from a phase 1b study (2021) Palomba ML, Till BG, Park SI, Morschhauser F, Cartron G, Marks R, Shivhare M, Hong WJ, Raval A, Change AC, Penuel E, Popplewell LL Clinical Lymphoma Myeloma and Leukemia
Back To Top
2020
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma (2020) Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, Salles G, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R American Journal of Hematology
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. (2020) Wick A, Desjardins A, Suarez C, Forsyth P, Gueorguieva I, Burkholder T, Cleverly AL, Estrem ST, Wang S, Lahn MM, Guba SC, Capper D, Rodon J Investigational New Drugs
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-ßRI inhibitor galunisertib. (2020) Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, Smith C, Estrem ST, Man M, Wang S, Lahn MM, Raymond E, Benhadji KA, Faivre S PLoS One
Elevated serum interlukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors (2020) Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, Walsh AM, Baxi V, Pandya D, Baradet T, Locke D, Wu Q, Reilly TP, Phillips P, Nagineni V, Gianino N, Gu J, Zhao H, Perez-Gracia JL, Snmamed MF, Melero I Nature Medicine
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition (2020) Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, Weber J Journal for ImmunoTherapy of Cancer
Fibroblasts from distinct pancreatic pathologies exhibit disease-specific properties (2020) Barrera LN, Evans A, Lane B, Brumskill S, Oldfield FE, Campbell F, Andrews T, Lu Z, Perez-Mancera PA, Liloglou T, Ashworth M, Jalali M, Dawson R, Nunes Q, Phillips PA, Timms JF, Halloran C, Greenhalf W, Neoptolemos JP, Costello E Cancer Research
A phase I study of ASTX660, an antagonist of inhibitors of apoptosis proteins, in adults with advanced cancers or lymphoma (2020) Mita MM, LoRusso PM, Papadopoulos KP, Gordon MS, Mita AC, Ferraldeschi R, Keer H, Oganesian A, Su XY, Jueliger S, Tolcher AW Clinical Cancer Research
Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium bacillus calmette guerin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy (2020) Rentsch CA, Bosshard P, Mayor G, Rieken M, Puschel H, Wirth G, Cathomas R, Parzmair GP, Grode L, Eisele B, Sharma H, Gupta M, Gairola S, Shaligram U, Goldenberger D, Spertini F, Audran R, Enoui M, Beradi S, Hayoz S, Wicki A Oncoimmunology
Model informed dosing regimen and phase I results of the anti-PD-1 antibody budigalimab (ABBV-181) (2020) Powderly J, Spira A, Kondo S, Doi T, Luke JL, Rasco D, Gao B, Tanner M, Cassier PA, Gazzah A, Italiano A, Tosi D, Afar DE, Parikh A, Engelhardt B, Englert S, Lambert SL, Kasichayanula S, Mensing S, Menon R, Vosganian G, Tolcher A Clinical and Translational Science
Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes (2020) Adams SF, Grimm AJ, Chiang CLL, Mookerjee A, Flies D, Jean S, McCann GA, Michaux J, Pak H, Huber F, Neal C, Dangaj D, Bassani-Sternberg M, Rusakiewicz S, Facciabene A, Coukos G, Gimotty PA, Kandalaft LE Journal for ImmunoTherapy of Cancer
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,30dioxygenase 2, in patients with advanced solid tumors (2020) Naing A, Eder JP, Piha-Paul SA, Gimmi C, Hussey E, Zhang S, Hildebrand V, Hosagrahara V, Habermehl C, Moisan J, Papadopoulos KP Journal for ImmunoTherapy of Cancer
HepatoScore-14: Measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk (2020) Morris JS, Hassan MM, Zohner YE, Wang Z, Xiao L, Rashid A, Haque A, Abdel-Wahab R, Mohamed YA, Ballard KL, Wolff RA, George B, Li L, Allen G, Weylandt M, Li D, Wang W, Raghav K, Yao J, Amin HM, Kaseb AO Heptology
First-in-human, single- and multiple-ascending dose studies in healthy subjects to assess pharmacokinetics, pharmacodynamics, and safety/tolerability of iberdomide, a novel cereblon E3 ligase modulator (2020) Ye Y, Gaudy A, Schafer P, Thomas M, Weiss D, Chen N, Liu L, Xue Y, Carayannopoulos L, Palmisano M Clinical Pharmacology in Drug Development
Back To Top
2019
TGFb receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer (2019) Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplangue G, Fuchs M, Trojan J, Kozloff M, Simionato F, Cleverly A, Smith C, Wang S, Man M, Driscoll KE, Estrem ST, Lahn MMF, Benhadji KA, Tabernero J Cancer Chemotherapy and Pharmacology
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. (2019) Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, Zha Z, Lim SO , Lai YJ, Liu C, Liu J, Dong Q, Yang Y, Sun L, Wei Y, Nie L, Hsu JL, Li H, Ye Q, Hassan MM, Amin HM, Kaseb AO, Lin X, Wang SC, Hung MC The Journal of Clinical Investigation
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. (2019) Molinero L, Li Y, Chang CW, Maund S, Berg M, Harrison J, Fasso M, O'Hear C, Hedge P, Emens LA Journal for ImmunoTherapy of Cancer
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors (2019) Piha-Paul SA, Hann CL, French CA, Cousin S, Brana I, Cassier PA, Moreno V, de Bono JS, Duckworth Harward S, Ferron-Brady G, Barbash O, Wyce A, Wu Y, Horner T, Annan M, Parr NJ, Prinjha RK, Carpenter CL, Hilton J, Hong DS, Hass NB, Markowski MC, Dhar A, O'Dwyer PJ, Shapiro GI JNCI Cancer Spectrum
A Machine-Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma. (2019) Wang R, Shao X, Zheng J, Saci A, Qian X, Pak I, Roy A, Bello A, Rizzo JI, Hosein F, Moss RA, Wind-Rotolo M, Feng Y Clinical Pharmacology and Therapeutics
A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. (2019) Rammensee HG, Wiesmuller KH, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, Kowalewski DJ, Di Marco M, Haen SP, Walz JS, Gloria YC, Bodder J, Schertel JM, Tunger A, Muller L, Kiebler M, Wehner R, Schmitz M, Jakobi M, Schneiderhan-Marra N, Klein R, Laske K, Artzner K, Backert L, Schuster H, Schwenck J, Weber ANR, Pichler BJ, Kneilling M, la Fougere C, Forchhammer S, Metzler G, Bauer J, Weide B, Schippert W, Stevanovic S, Loffler MW Journal for ImmunoTherapy of Cancer
Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma. (2019) Wang R, Zheng J, Shao X, Ishii Y, Roy A, Bello A, Lee R, Zhang J, Wind-Rotolo M, Feny Y Journal for ImmunoTherapy of Cancer
Back To Top
2018
Phase Ib Study of Glasdegib, A Hedgehog Pathway Inhibitor, in (2018) Savona M, Pollyea D, Stock W, Oehler V, Schroeder MA, Lancet J, McCloskey J, Kantarigian H, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE Clinical Cancer Research
Carbon nanotube and nanofiber exposure and sputum and blood biomarkers of early effect among U.S. workers (2018) Beard JD, Erdely A, Dahm MM, de Perio MA, Birch ME, Evans DE, Fernback JE, Eye T, Kodali V, Mercer RR, Bertke SJ, Schubauer-Berigan MK Environmental Internation 116 (2018)
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer (2018) Calcinottoa A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, De Bernardis G, Losa M, Mirenda M, Pasquini E, Rinaldi A, Sumanasuriya S, Lambros MB, Neeb A, Luciano R, Bravi CA, Nava-Rodriques D, Dolling D, Prayer-Galetti T, Ferreira A, Briganti A, Esposito A, Barry S, Yuan W, Sharp A, de Bono J, Alimonti A Nature
Dose escalation results from a first-in-human, phase I study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors (2018) Tran B, Carvajal RD, Marabelle A, Patel SP, LoRusso PM, Rasmussen E, Juan G, Upreti VV, Beers C, Ngarmchamnanrith G, Schoffski P Journal for ImmunoTherapy of Cancer
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103) (2018) Lindemann K, Beale PJ, Rossi E, Goh JC, Vaughan MM, Tenney ME, Martyn JK, Sommeijer D, Iglesias JL, Kremmidiotis G, Simpson J, Doolin E, Lavranos TC, Veillard AS, Espinoza D, Stockler MR, Rischin D Cancer Chemotherapy and Pharmacology
Phase I/II trial of combination of anti-CD3/CD7 immunotoxins for steroid-refractory acute graft-versus-host disease (2018) Groth C, van Groningen LFJ, Matos TR, Bremmers ME, Preijers FWMB, Dolstra H, Reicherts C, Schaap NPM, van Hooren EHG, IntHout J, Masereeuw R, Netea MG, Levine JE, Morales G, Ferrara JL, Blijlevens NMA, van Oosterhout YVJM, Stelljes M, van der Velden WJFM Biology of Blood and Marrow Transplantation
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients (2018) Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Levegue J, Tannir NM, Oft M Cancer Cell
Serum Apolipoprotein E and Other Inflammatory Markers Can Identify Non-Responding Patients to a Dendritic Cell Vaccine (2018) Leeman H, Kaminska E, Green D, Bodman-Smith M, Gravett A, Bodman-Smith K, Copier J, Coulton G, Fusi A, Dalgleish AG Translational Oncology
Back To Top
2017
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy (2017) Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM and Butterfield LH J Immunother Cancer
Assessing biological and technological variability in protein levels measured in pre-diagnostic plasma samples of women with breast cancer. (2017) Yeh CY, Adusumilli R, Kullolli M, Mallick P, John EM, Pitteri SJ Biomark Res.
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. (2017) Steggerda SM, Bennett MK, Chen J, Emberley E, Huang T, Janes JR, Li W, MacKinnon AL, Makkouk A, Marguier G, Murray PJ, Neou S, Pan A, Parlati F, Rodriguez MLM, Van de Velde LA, Wang T, Works M, Zhang J, Zhang W, Gross MI J Immunother Cancer
The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles (2017) Loges S, Gjertsen BT, Heuser M, Chromik J, Ben-Batalla I, Akyuz N, Micklem D, Brown A, Lorens J, Yule M, Kebenko M, Janning M, Binder M, Fiedler W, Cortes J Blood
Back To Top
2016
Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity (2016) Dietsch GN, Lu H, Yang Y, Morishima C, Chow LQ, Disis ML, Hershberg RM PLoS ONE
Immune Monitoring Technology Primer: Immunoprofiling of Antigen-Stimulated Blood (2016) Brunet LR, LaBrie S, Hagemann T Journal for Immunotherapy of Cancer
Effect of Low-Magnitude, High-Frequency Mechanical Stimulation on Bmd among Young Childhood Cancer Survivors: A Randomized Clinical Trial (2016) Mogil RJ, Kaste SC, Ferry Jr RJ, Hudson MM, Mulrooney DA, Howell CR, Partin RE, Srivastava DK, Robison LL, Ness KK JAMA Oncology
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (2016) Choueiri TK, Fishman M, Escudier B, McDermott DF, Drake CG, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen LJ, Young TC, Chasalow SD, Ross-MacDonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M Clinical Cancer Research
Circulating Biomarkers and Outcome from a Randomised Phase Ii Trial of Sunitinib Vs Everolimus for Patients with Metastatic Renal Cell Carcinoma (2016) Voss MH, Chen D, Marker M, Hakimi AA, Lee C-H, Hsieh JJ, Knox JJ, Voi M, Motzer RJ British Journal of Cancer
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (Am0010) in Patients with Advanced Solid Tumors (2016) Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR Journal of Clinical Oncology
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer (2016) Saif MW, Knost JA, Chiorean EG, Kambhampati SR, Yu D, Pytowski B, Qin A, Kauh JS, O'Neil BH Cancer Chemother Pharmacol
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (2016) Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J. Cancer
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. (2016) Söderlund S, Christiansson L, Persson I, Hjorth-Hansen H, Richter J, Simonsson B, Mustjoki S, Olsson-Strömberg U, Loskog A. Leuk Res
Primary Analysis Of A Phase II Open-Label Trial Of INCB039110, A Selective JAK1 Inhibitor, In Patients With Myelofibrosis (2016) Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, Paquette R, Turner AR, Coughlin P, Winton E, Burn TC, O'Neill P, Clark J, Hunter D10, Assad A, Hoffman R, Verstovsek S Haematologica
Back To Top
2015
Phase II Evaluation of IPI-926, an Oral Hedgehog Inhibitor, in Patients with Myelofibrosis. (2015) Sasaki K, Gotlib JR, Mesa RA, Newberry KJ, Ravandi F, Cortes JE, Kelly P, Kutok JL, Kantarjian HM, Verstovsek S. Leuk Lymphoma. 2015 Feb 2:1-20. [Epub ahead of print]
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses. (2015) Christiansson L, Soderlund S, Mangsbo SM, Hjorth-Hansen H, Höglund M, Markevarn B, Richter J, Stenke L, Mustjoki S, Loskog A, Olsson-Stromberg U. Mol Cancer Ther. 2015 Mar 11. pii: molcanther.0849.2014. [Epub ahead of print]
Late Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337) (2015) Dietsch GN, Randall TD, Gottardo R, Northfelt DW, Ramanathan RK, Cohen PA, Manjarrez KL, Newkirk M, Bryan JK, Hershberg RM Clinical Cancer Research
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (2015) Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, Xu C, Cao H and Talpaz M Blood Cancer Journal
Identification of plasma biomarker concentration changes resulting from the administration of the Vascular Disrupting Agent BNC105 across 3 clinical trials in mesothelioma, ovarian and renal cancer (2015) Kremmidiotis G, Leske A, Simpson J, Doolin E, Iglesias J AACR 2015
Biomarker results from a clinical trial of nivolumab in patients (pts) with metastatic renal cell carcinoma (mRCC) (CA209-009): Gene expression, serum profiling for immune markers, and multiplex tissue immunohistochemistry (IHC) (2015) Choueiri TK, Fishman MN, Escudier B, Stadler WM, Chasalow S, Ross-Macdonald P, Jure-Kunkel M, Sznol M, and Simon JS Cancer Res
Common Effects on Cancer Cells Exerted by a Random Positioning Machine and a 2D Clinostat (2015) Svejgaard B, Wehland M, Ma X, Kopp S, Sahana J, Warnke E, Aleshcheva G, Hemmersbach R, Hauslage J, Grosse J, Bauer J, Corydon TJ, Islam T, Infanger M, Grimm D PLoS One
A Phase 1 Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma (2015) Amaravadi RK, Schilder RJ, Martin LP, Levin M, Graham MA, Weng DE, Adjei AA Mol Cancer Ther.
Neuropilin 1 (NRP1) may be prognostic and identify a subgroup of Patients with Metastatic Colorectal Cancer (mCRC) who Benefit from Tivozanib + mFOLFOX6 compared to Bevacizumab + mFOLFOX6 (2015) Benson A, Krivoshik A, Van Sant C, Needle M Annals of Oncology
Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use (2015) Srivastava AK, Jaganathan S, Stephen L, Hollingshead MG, Govindharajulu JP, Layhee A, Damour E, Donohue J, Esposito D, Mapes JP, Kinders R, Takebe N, Tomaszewski JE, Kummar S, Doroshow JH, Parchment RE Clinical Cancer Research
BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages (2015) Rosati A, Basile A, D'Auria R, d'Avenia M, De Marco M, Falco A, Festa M, Guerriero L, Iorio V, Parente R, Pascale M, Marzullo L, Franco R, Arra C, Barbieri A, Rea D, Menichini G, Hahne M, Bijlsma M, Barcaroli D, Sala G, di Mola FF, di Sebastiano P, Todoric J, Antonucci L, Corvest V, Jawhari A, Firpo MA, Tuveson DA, Capunzo M, Karin M, De Laurenzi V, Turco MC. Nat Commun.
Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab (2015) Sznol M, Fishman M, Escudier B, McDermott DF, Kluger H, Stadler WM, Perez-Gracia J, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman L, Fong L, Drake CG, Young TC, Chasalow SD, Ross-MacDonald P, Simon JS, Walker D, Choueiri TK J Immunother Cancer
Identification of circulatory biomarkers from clinical trial samples (2015) Brunet LR, Bodman-Smith K, Bodman-Smith M, Kassam Z, Dalgleish A, LaBrie S and Hagemann T J Immunother Cancer
Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer (2015) Pommier AJC, Farren M, Patel B, Wappett M, Michopoulos F, Smith NR, Kendrew J, Frith J, Huby R, Eberlein C, Campbell H, Womack C, Smith PD, Robertson J, Morgan S, Critchlow SE, Barry ST Cell Metabolism
Phase I Trial of the Pan-Pi3k Inhibitor Pilaralisib (Sar245408/Xl147) in Patients with Chronic Lymphocytic Leukemia (Cll) or Relapsed/Refractory Lymphoma (2015) Brown JR, Davids MS, Rodon J, Abrisqueta P, Kasar SN, Lager J, Jiang J, Egile C, Awan FT American Association for Cancer Research
Intratumoral Inf-g Triggers an Antiviral State in Gl261 Tumor Cells: A Major Hurdle to Overcome for Oncolytic Vaccinia Virus Therapy of Cancer (2015) Kober C, Weibel S, Rohn S, Kirscher L, Szalay AA*2015*Intratumoral Inf-G Triggers an Antiviral State in Gl261 Tumor Cells: A Major Hurdle to Overcome for Oncolytic Vaccinia Virus Therapy of Cancer Molecular Therapy — Oncolytics
A Phase I/Ii Trial of Bnc105p with Everolimus in Metastatic Renal Cell Carcinoma (2015) Pal S, Azad A, Bhatia S, Drabkin H, Costello B, Sarantopoulos J, Kanesvaran R, Lauer R, Starodub A, Hauke R, Sweeney CJ, Hahn NM, Sonpavde G, Richey S, Breen T, Kremmidiotis G, Leske A, Doolin E, Bibby DC, Simpson J, Iglesias J, Hutson T Clinical Cancer Research
Back To Top
2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors (2014) Weekes CD, Beeram M, Tolcher AW, Papadopoulos KP, Gore L, Hegde P, Xin Y, Yu R, Shih LM, Xiang H, Brachmann RK, Patnaik A Invest New Drugs. 2014 Mar 7. [Epub ahead of print]
A Phase 1 Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX 2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma (2014) Northfelt DW, Ramanathan RK, Cohen PA, Von Hoff DD, Weiss GJ, Dietsch GN, Manjarrez KL, Randall TD, Hershberg RM Clin Cancer Res. 2014 May 7
Spheroid formation of human thyroid cancer cells (2014) Warnke E, Pietsch J, Wehland M, Bauer J, Infanger M, Görög M, Hemmersbach R, Braun M, Ma X, Sahana J, Grimm D Cell Communication and Signaling 2014, 12:32
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study (2014) Brana I, Calles A, LoRusso PM, Yee LK, Puchalski TA, Seetharam S, Zhong B, de Boer CJ, Tabernero J, Calvo E Target Oncol. 2014 Jun 15
Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice (2014) Hofmann E, Weibel S, Szalay AA Journal of Translational Medicine 2014 Jul 17;12:197. doi: 10.1186/1479-5876-12-197
Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib. (2014) Pommier AJ, Shaw R, Spencer SK, Morgan SR, Hoff PM, Robertson JD, Barry ST, Jürgensmeier JM. British Journal of Cancer 2014 Aug 14. doi: 10.1038/bjc.2014.436. [Epub ahead of print]
Fat Quality and Incident Cardiovascular Disease, All-Cause Mortality and Cancer Mortality (2014) Rosenquist KJ, Massaro JM, Pedley A, Long MT, Kreger BE, Vasan RS, Murabito JM, Hoffmann U, Fox CS. Journal of Clinical Endocrinology & Metabolism 2014 Sep 16:jc20134296. [Epub ahead of print]
A phase I dose-escalation study to a predefined dose of a transforming growth factor-ß1 monoclonal antibody (TßM1) in patients with metastatic cancer (2014) Cohn A, Lahn MM, Williams KE, Cleverly AL, Pitou C, Kadam SK, Farmen MW, Desaiah D, Raju R, Conkling P, Richards D International Journal of Oncology 10.3892/ijo.2014.2679
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (XL765), an orally administered PI3K/mTOR inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. (2014) Papadopoulos KP, Egile C, Ruiz-Soto R, Jiang J, Shi W, Bentzien F, Rasco D, Abrisqueta P, Vose JM, Tabernero J. Informa Healthcare Leuk Lymphoma. 2014 Oct 10:1-32. [Epub ahead of print]
TRAMP Prostate Tumor Growth Is Slowed by Walnut Diets Through Altered IGF-1 Levels, Energy Pathways, and Cholesterol Metabolism (2014) Kim H, Yokoyama W, Davis PA. J Med Food. 2014 Oct 29. [Epub ahead of print]
First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors. (2014) Schultheis B, Strumberg D, Santel A, Vank C, Gebhardt F, Keil O, Lange C, Giese K, Kaufmann J, Khan M, Drevs J. J Clin Oncol. 2014 Nov 17. pii: JCO.2013.55.0376. [Epub ahead of print]
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. (2014) Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. Nature. 2014 Nov 26;515(7528):558-62. doi: 10.1038/nature13904.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. (2014) Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Nature. 2014 Nov 26;515(7528):563-7. doi: 10.1038/nature14011.
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-ß receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. (2014) Rodón J, Carducci M, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly A, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. Invest New Drugs. 2014 Dec 23. [Epub ahead of print]
Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I. (2014) Mesa RA, Verstovsek S, Gupta V, Mascarenhas J, Atallah E, Burn T, Sun W, Sandor V, Gotlib J. Clin Lymphoma Myeloma Leuk [Epub ahead of print]
Back To Top
2013
Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4 (2013) O'Shannessy DJ, Somers EB, Palmer LM, Thiel RP, Oberoi P, Heath R, Marcucci L Journal of Ovarian Research 2013, 6:29
Multi-analyte profiling and pathway analysis of plasma for proteins associated with cancer-related fatigue syndrome in disease-free breast cancer patients after primary treatment (2013) Minton O, Coulton GR, Stone P BMJ Support Palliat Care doi:10.1136/bmjspcare-2013-000452
A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma (2013) Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, Kremmidiotis G, Bibby DC, Leske AF, Mitchell PL, Pavlakis N, Boyer M, Stockler MR Lung Cancer. 2013 Jun 17. pii: S0169-5002(13)00218-3
Impact of Sunitinib on Human Thyroid Cancer Cells (2013) Grosse J, Warnke E, Pohl F, Magnusson NE, Wehland M, Infanger M, Eilles C, Grimm D Cell Physiol Biochem. 2013 Jul 12;32(1):154-170
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy (2013) Spencer SK, Pommier AJ, Morgan SR, Barry ST, Robertson JD, Hoff PM, Jürgensmeier JM Br J Cancer. 2013 Oct 22
A Multicenter Phase II Study of Single-agent Enzastaurin in Previously Treated Multiple Myeloma (2013) Jourdan E, Leblond V, Maisonneuve H, Benhadji KA, Hossain AM, Nguyen TS, Wooldridge JE, Moreau P Leuk Lymphoma. 2013 Nov 3. [Epub ahead of print]
Biomarker identification in serum samples from patients with recurrent cervical cancer treated with ADXS11-001 immunotherapy (2013) Molli P, Malinina I, Wallecha A Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P61
Differential gene expression profile and altered cytokine secretion of thyroid cancer cells in space (2013) Ma X, Pietsch J, Wehland M, Schulz H, Saar K, Hübner N, Bauer J, Braun M, Schwarzwälder A, Segerer J, Birlem M, Horn A, Hemmersbach R, Waßer K, Grosse J, Infanger M, Grimm D FASEB J. 2013 Nov 6. [Epub ahead of print]
Cytokine Profile Changes In 309 Myelofibrosis Patients: Comparison Of JAK1/JAK2 Inhibitor Therapy Vs. Placebo – Correlative Analysis From The Comfort-I Trial (2013) Dueck AC, Cleeland CS, Dantzer R, Sloan J, Verstovsek S, Emanuel RM, Geyer HL, Mesa RA Blood October 21, 2013 vol. 122 no. 21 4074
First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors (2013) Mross K, Richly H, Fischer R, Scharr D, Büchert M, Stern A, Gille H, Audoly LP, Scheulen ME PLoS One. 2013 Dec 13;8(12):e83232
The Senescence-Associated Secretory Phenotype In Multiple Myeloma (2013) Wildes TM, Paasch J, Fiala MA, Chen L, Vij R, Stockerl-Goldstein KE, Stewart S, Colditz GA,Tomasson M Blood October 21, 2013 vol. 122 no. 21 5357
A Canonical Transforming Growth Factor Beta-Dependent Signaling Pathway is Present in Peripheral Blood Cells of Cancer Patients with Skeletal Metastasis (2013) Kadam S, Cleverly AL, Farmen M, Grondin J, Cox YI, Lahn M J Mol Biomark Diagn 2013, 4:3
Update on the Safety and Efficacy of the Pan Class I Pi3k Inhibitor Sar245408 (Xl147) in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients (2013) Davids MS, Rodon J, Abrisqueta P, Egile C, Ruiz-Soto R, Awan F Blood
Rg7212 Anti-Tweak Mab Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response (2013) Yin X, Luistro L, Zhong H, Smith M, Nevins T, Schostack K, Hilton H, Lin T-A, Truitt T, Biondi D, Wang X, Packman K, Rosinski J, Berkofsky-Fessler W, Tang J-P, Pant S, Geho D, Vega-Harring S, Demario M, Levitsky H, Simcox M American Association for Cancer Research
Back To Top
2012
Supernatants derived from chemotherapy-treated cancer cell lines can modify angiogenesis (2012) Liu WM, Dennis JL, Gravett AM, Chanthirakumar C, Kaminska E, Coulton G, Fowler DW, Bodman-Smith M, Dalgleish AG Br J Cancer. 2012 Jan 31 [Epub ahead of print]
STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma (2012) Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ, MacKeigan JP PLoS ONE 7(2): e30820
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis (2012) Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM N Engl J Med. 2012 Mar;366(9):799-807
Preferential Replication of Systemically Delivered Oncolytic Vaccinia Virus in Focally Irradiated Glioma Xenografts (2012) Advani SJ, Buckel L, Chen NG, Scanderbeg DJ, Geissinger U, Zhang Q, Yu YA, Aguilar RJ, Mundt A, Szalay AA Clin Cancer Res. 2012 Feb 29. [Epub ahead of print]
Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes (2012) Willard MD, Lajiness ME, Wulur IH, Feng B, Swearingen ML, Uhlik MT, Kinzler KW, Velculescu VE, Sjöblom T, Markowitz SD, Powell SM, Vogelstein B, Barber TD Mol Cancer Res. 2012 Apr 19
Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors (2012) Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ J Clin Oncol. 2012 Apr 23
Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma (2012) Xu BJ, An QA, Srinivasa Gowda S, Yan W, Pierce LA, Abel TW, Rush SZ, Cooper MK, Ye F, Shyr Y, Weaver KD, Thompson RC Int J Oncol. 2012 Jun;40(6):1995-2003
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival (2012) Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H Nat Med. 2012 Jul 29. doi: 10.1038/nm.2883. [Epub ahead of print]
Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences (2012) Eve HE, Carey S, Richardson SJ, Heise CC, Mamidipudi V, Shi T, Radford JA, Auer RL, Bullard SH, Rule SA Br J Haematol. 2012 Aug 9.
A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia (2012) Ghobrial IM, Moreau P, Harris B, Poon T, Jourdan E, Maisonneuve HM, Benhadji KA, Hossain A, Nguyen T, Wooldridge JE, Leblond V Clin Cancer Res. 2012 Aug 9
Preferential Colonization of Metastases by Oncolytic Vaccinia Virus Strain GLV-1h68 in a Human PC-3 Prostate Cancer Model in Nude Mice (2012) Donat U, Weibel S, Hess M, Stritzker J, Härtl B, Sturm JB, Chen NG, Gentschev I, Szalay AA PLoS ONE 7(9): e45942
Identification of factors associated with cancer related fatigue syndrome in disease-free breast cancer patients after completing primary treatment (2012) Minton O, Alexander S, Stone PC Breast Cancer Res Treat. 2012 Oct 14. [Epub ahead of print]
Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis (2012) Wong H, Budha NR, West K, Blackwood E, Ware JA, Yu R, Darbonne WC, Gould SE, Steigerwalt R, Erickson R, Hop CE, LoRusso P, Eckhardt SG, Wagner A, Chan IT, Mamounas M, Flygare JA, Fairbrother WJ Toxicol Sci. 2012 Nov;130(1):205-13
Defining Map3 Kinases Required for Mda-Mb-231 Cell Tumor Growth and Metastasis (2012) Cronan MR, Nakamura K, Johnson NL, Granger DA, Cuevas BD, Wang JG, Mackman N, Scott JE, Dohlman HG, Johnson GL Oncogene
Targeting Tnf-? to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy (2012) Calcinotto A, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani G, Corti A, Bellone M Journal of Immunology
Back To Top
2011
High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the gamma-secretase inhibitor, RO4929097 (2011) He W, Luistro L, Carvajal D, Smith M, Nevins T, Yin X, Cai J, Higgins B, Kolinsky K, Rizzo C, Packman K, Heimbrook D, Boylan JF Molecular Oncology [Epub ahead of print]
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma (2011) Ghobrial IM, Munshi NC, Harris BN, Shi P, Porter NM, Schlossman RL, Laubach JP, Anderson KC, Desaiah D, Myrand SP, Wooldridge JE, Richardson PG, Abonour R Am. J. Hematol.
Molecular indicators of non-sentinel node status in breast cancer determined in preoperative biopsies by multiplexed sandwich immunoassays (2011) Sauer G, Schneiderhan-Marra N, Muche R, Koretz K, Kazmaier C, Kreienberg R, Joos T, Deissler H J Cancer Res Clin Oncol. 2011 Apr 24. [Epub ahead of print]
Tumor Microenvironment-Derived Proteins Dominate the Plasma Proteome Response During Breast Cancer Induction and Progression (2011) Pitteri SJ, Kelly-Spratt KS, Gurley KE, Kennedy J, Busald Buson T, Chin A, Wang H, Zhang Q, Wong CH, Chodosh LA, Nelson PS, Hanash SM, Kemp CJ Cancer Res. 2011 Jun 8. [Epub ahead of print]
Efficient Colonization and Therapy of Human Hepatocellular Carcinoma (HCC) Using the Oncolytic Vaccinia Virus Strain GLV-1h68 (2011) Gentschev I, Müller M, Adelfinger M, Weibel S, Grummt F, Zimmermann M, Bitzer M, Heisig M, Zhang Q, Yu YA, Chen NG, Stritzker J, Lauer UM, Szalay AA PLoS ONE 6(7): e22069
STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia (2011) Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG, Zimmers TA PLoS ONE 6(7): e22538
Host-derived osteopontin maintains an acute inflammatory response to suppress early progression of extrinsic cancer cells (2011) Hsieh YH, Juliana MM, Ho KJ, Kuo HC, van der Heyde H, Elmets C, Chang PL Int J Cancer. 2011 Aug 8. doi: 10.1002/ijc.26359. [Epub ahead of print]
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells (2011) Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G Nature. 2011 Jul 13;475(7355):226-30
Mycobacteria activate gamma delta T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy (2011) Fowler DW, Copier J, Wilson N, Dalgleish AG, Bodman-Smith MD Cancer Immunol Immunother. 2011 Oct 15. [Epub ahead of print]
Bone Marrow Derived Mesenchymal Stromal Cells are Attracted by Multiple Myeloma Cell-Produced Chemokine CCL25 and Favor Myeloma Cell Growth In Vitro and In Vivo (2011) Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I Stem Cells. 2011 Nov 18. [Epub ahead of print]
A novel detection method of non-small cell lung cancer using multiplexed bead-based serum biomarker profiling (2011) Lee HJ, Kim YT, Park PJ, Shin YS, Kang KN, Kim Y, Kim CW J Thorac Cardiovasc Surg. 2011 Nov 18. [Epub ahead of print]
Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers (2011) Yip P, Chen TH, Seshaiah P, Stephen LL, Michael-Ballard KL, Mapes JP, Mansfield BC, Bertenshaw GP PLoS One. 2011;6(12):e29533. Epub 2011 Dec 21
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial (2011) Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM Lancet Oncol. 2011 Nov;12(12):1125-33
Back To Top
2010
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis (2010) Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A N Engl J Med. 363: 1117-27.
Validation of a Multivariate Serum Profile for Epithelial Ovarian Cancer Using a Prospective Multi-Site Collection (2010) Seshaiah P, Bertenshaw GP, Chen TH, Bergstrom KJ, Zhao J, Mapes JP, Stephen LL, Amonkar S, McCollum ME, Miller BE, Roman LD, Karlan BY, Chalas E, DiSilvestro PA, Barter JF, Orr Jr JW, Bigsby IV GE, Holloway RW, Alvarez RD, Yip PF, Mansfield BC Nature Precedings Jul 2010.
Significant growth inhibition of canine mammary carcinoma xenografts following treatment with oncolytic vaccinia virus GLV-1h68 (2010) Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, Yu YA, Zhang Q, Bullerdiek J, Nolte I, Stritzker J, Szalay AA J Oncol. 2010:736907. Epub 2010 Jun 23
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma. (2010) Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, Teh BT Cancer Res 70: 1063-1071.
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. (2010) Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, Macarulla T, Rodriguez-Braun E, Eugenia Vega-Villegas M, Senger S, Ramos FJ, Roselló S, Celik I, Stroh C, Baselga J, Ciardiello F J Clin Oncol 28: 1181-1189.
Identification of breast cancer biomarkers in transgenic mouse models: a proteomics approach. (2010) Rodenburg W, Pennings JLA, van Oostrom CTM, Roodbergen M, Kuiper RV, Luijten M, de Vries A Proteomics Clin Appl. 4: 602-612.
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. (2010) Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V, Heymach JV, Atkins MB, McDermott D, Sukhatme VP Cancer 116: 1751-1756.
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours (2010) Gregorc V, Citterio G, Vitali G, Spreafico A, Scifo P, Borri A, Donadoni G, Rossoni G, Corti A, Caligaris-Cappio F, Del Maschio A, Esposito A, De Cobelli F, Dell'Acqua F, Troysi A, Bruzzi P, Lambiase A, Bordignon C Eur J Cancer. 46: 198-206.
Metronomic Gemcitabine Suppresses Tumour Growth, Improves Perfusion, and Reduces Hypoxia in Human Pancreatic Ductal Adenocarcinoma (2010) Cham KKY, Baker JHE, Takhar KS, Flexman JA, Wong MQ, Owen DA, Yung A, Kozlowski P, Reinsberg SA, Chu EM, Chang CWA, Buczkowski AK, Chung SW, Scudamore CH, Minchinton AI, Yapp DTT, Ng SSW British Journal of Cancer
Back To Top
2009
Western-style diets induce oxidative stress and dysregulate immune responses in the colon in a mouse model of sporadic colon cancer (2009) Erdelyi I, Levenkova N, Lin EY, Pinto JT, Lipkin M, Quimby FW, Holt PR J Nutr. 139: 2072-8.
The multiplex bead array approach to identifying serum biomarkers associated with breast cancer (2009) Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, Lee KA, Ye S, Hyun H, Kang KN, Yeo D, Kim Y, Ohn SY, Noh DY, Kim CW Breast Cancer Res. 11: R22.
Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder Cancer. (2009) Bisiaux A, Thiounn N, Timsit MO, Eladaoui A, Chang HH, Mapes J, Mogenet A, Bresson JL, Prié D, Béchet S, Baron C, Sadorge C, Thomas S, Albert EB, Albert PS, Albert ML J Urol 181: 1571-1580.
Immune Activation in Advanced Cancer Patients Treated with Recombinant IL-21: Multianalyte Profiling of Serum Proteins. (2009) Dodds MG, Frederiksen KS, Skak K, Hansen LT, Lundsgaard D, Thompson JA, Hughes SD Cancer Immunol Immunother 58: 843-854.
Regression of Human Pancreatic Tumor Xenografts in Mice After a Single Systemic Injection of Recombinant Vaccinia Virus GLV-1h68. (2009) Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, Fong Y, Szalay AA Mol Cancer Ther 8: 141-151.
Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer. (2009) Debucquoy A, Haustermans K, Daemen A, Aydin S, Libbrecht L, Gevaert O, De Moor B, Tejpar S, McBride WH, Penninckx F, Scalliet P, Stroh C, Vlassak S, Sempoux C, Machiels JP J Clin Oncol 27: 2751-2757.
Development and Preliminary Evaluation of a Multivariate Index Assay for Ovarian Cancer. (2009) Amonkar SD, Bertenshaw GP, Chen TH, Bergstrom KJ, Zhao J, Seshaiah P, Yip P, Mansfield BC PLoS ONE 4: e4599.
Back To Top
2008
TGF-beta signalling-related markers in cancer patients with bone metastasis. (2008) Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Arteaga C, Carducci M Biomarkers 13: 217-236.
Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. (2008) Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, Mapes JP, Mansfield BC Cancer Epidemiol Biomarkers Prev 17: 2872-81.
Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. (2008) Ding Y, Boguslawski EA, Berghuis BD, Young JJ, Zhang Z, Hardy K, Furge K, Kort E, Frankel AE, Hay RV, Resau JH, Duesbery NS Mol Cancer Ther 7: 648-658.
A mouse to human search for plasma proteome changes associated with pancreatic tumor development. (2008) Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, Hanash SM PLoS Med 5: e123.
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. (2008) Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G J Clin Oncol 26: 1135-1141.
Back To Top
2007
Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. (2007) Caers J, Deleu S, Belaid Z, De Raeve H, Van Valckenborgh E, De Bruyne E, Defresne MP, Van Riet I, Van Camp B, Vanderkerken K Leukemia 21: 1580-1584.
Back To Top
2006
Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. (2006) Singh M, Johnson L Clin Cancer Res 12: 5312-5328.
Effects of the incubation in vitro with sorbents on serum proteomic pattern and cytokine concentration in cancer patients during chemotherapy--preliminary results. (2006) Piccolomini F, LouWratten M, Sereni L, Balestreri E, Donadio E, Felicioli A, Felicioli R, Donadio C Biomed Pharmacother 60: 463-467.
Cardiovascular Application Notes
Application Notes, Cardiovascular
Subclinical Interstitial Lung Disease Detection: Role for Biomarker Profiling
Cardiovascular, Webinars
Every Order Starts With a Quote
Thank you for your interest in RBM's innovative biomarker solutions. Please tell us more about what you would like to order and provide us with your details, so we can get back to you with a quote.